Under the product code MPFF-PG-90/10, the API comprises 90.0% diosmin and 10.0% hesperidin on the dried basis, with release subgrades MPFF-PG-90/10-O for oral solid-dose manufacture and MPFF-PG-90/10-I for aqueous injectable suspension processing. HPLC assay and related-substances control follow Ph. Eur. 2.2.29; water content is determined by Ph. Eur. 2.5.12; residual solvents are limited under ICH Q3C using Ph. Eur. 2.4.24; elemental impurities are controlled under ICH Q3D and U.S.P. <232>/<233>. The oral grade is specified for tablet, capsule, and granule manufacture, while the injectable grade carries additional bacterial endotoxin testing per Ph. Eur. 2.6.14 and particulate matter testing per Ph. Eur. 2.9.19. This product differs from non-micronized and food-grade flavonoid fractions by its controlled particle-size distribution, fixed flavonoid ratio, reduced related-substance burden, and injectable-grade endotoxin envelope.

What Particle-Size and Flow Requirements Govern Tablet, Capsule, and Granule Processing?

Particle-size distribution is the central control parameter. Laser diffraction per ISO 13320:2020 is used to release oral-grade material with D50 between 2 µm and 5 µm and D90 not greater than 15 µm; the injectable subgrade is controlled at D50 not greater than 2 µm and D90 not greater than 5 µm. Micronization is conducted in fluidized-bed opposed-jet mills with classifier-controlled product withdrawal, which reduces thermal exposure during size reduction. The resulting powder is cohesive; bulk and tapped density determinations per Ph. Eur. 2.9.34 typically yield Carr index values above 25% and Hausner ratios above 1.30. On rotary tablet presses, this requires force-feeder assistance and precompression to evacuate air before main compression. Tablet disintegration is assessed by Ph. Eur. 2.9.1, and dissolution of diosmin from finished tablets is monitored by Ph. Eur. 2.9.3. High-shear wet granulation with purified water is preferred for granule manufacture; the API is chemically stable in water under acidic-to-neutral pH, and final water content is controlled to not more than 5.0% by Ph. Eur. 2.5.12. Capsule filling on dosator-type machines requires controlled bulk density; when relative humidity exceeds 60%, moisture uptake increases sticking and weight variability on production-scale equipment.

Specific surface area measured by Ph. Eur. 2.9.26 or ISO 9277:2022 increases as D50 decreases from 5 µm to 2 µm. Higher surface area accelerates dissolution of diosmin in surfactant-free media but also increases electrostatic charge and adhesion to punch faces. On production-scale capsule filling, static charge is controlled by maintaining relative humidity between 40% and 55%; below 40%, electrostatic repulsion reduces fill weight consistency, while above 60%, powder caking on dosator pins occurs. Granulation with water in a high-shear mixer at impeller tip speed 3–5 m/s reduces dust and improves tabletability but requires subsequent drying at inlet air temperature 50–70 °C until water content is not more than 5.0% by Ph. Eur. 2.5.12. Tablets compressed from the granulated material are tested for hardness, friability by Ph. Eur. 2.9.7, disintegration by Ph. Eur. 2.9.1, and dissolution by Ph. Eur. 2.9.3. The principal scale-up failure mode observed on 16-station B-tooling presses is lamination when granule moisture falls below 1.5%; precompression force at 20–35% of main compression force reduces this defect.

Injectable-grade processing begins with the same jet-milled flavonoid core but adds low-bioburden handling, nitrogen overlay during packaging, and terminal release testing for bacterial endotoxins and particulate matter. Diosmin and hesperidin are practically insoluble in water; therefore the injectable dosage form is a sterile aqueous suspension rather than a solution. Aseptic processing is generally selected over terminal steam sterilization because saturated steam at 121 °C accelerates hydrolytic degradation of the flavonoid skeleton. The API release limit for bacterial endotoxins is calculated from Ph. Eur. 5.1.10 using K = 5 EU/kg; for a 500 mg daily injectable dose in a 70 kg patient, the limit is not more than 0.7 EU/mg. Finished-injection particulate counts must comply with Ph. Eur. 2.9.19 for particles at 10 µm and 25 µm. The production bottleneck observed at scale is the agglomeration of micronized flavonoid particles when the powder is stored above 25 °C and 60% relative humidity; this raises D90 and creates filtration risk during aseptic filling. Re-micronization outside a validated classifier-controlled mill is not recommended because it can raise bioburden and shift particle-size distribution.

Pharmacopoeial Specifications, Residual-Solvent Limits, and Elemental-Impurity Control

Release specifications are derived from the Ph. Eur. Diosmin monograph and ICH guidance because a compendial monograph for the fixed micronized purified flavonoid fraction combination is not separately established. The table lists control parameters for the two subgrades.

Batch-to-batch variance is monitored by statistical process control on assay, related substances, and particle-size distribution. The API is manufactured under ICH Q7 good manufacturing practice, while finished oral and injectable forms are processed under 21 CFR 211. Stability protocols for the API and finished products follow ICH Q1A; long-term storage is evaluated at 25 °C/60% relative humidity and accelerated storage at 40 °C/75% relative humidity.

When Non-Micronized or Food-Grade Flavonoid Fractions Are Compared with MPFF-PG-90/10

Direct substitution with non-micronized or food-grade material is not equivalent because the products differ in particle size, flavonoid ratio, impurity profile, and parenteral readiness. Non-micronized pharma blends may have D90 above 40 µm, reducing dissolution velocity under Ph. Eur. 2.9.3 and requiring reformulation before tablet or capsule compression. Food-grade citrus extracts typically contain 60–80% total flavonoids and variable diosmin-to-hesperidin ratios, with residual pectin fragments, limonoids, and color bodies that are not controlled under ICH Q3D. The following table summarizes the technical differences.

Non-micronized materials also create compressibility differences. Larger particles generally improve flow but reduce tensile strength because fewer interparticulate contact points remain after compression; the compact may cap during decompression. Conversely, food-grade extracts may introduce hygroscopic polysaccharides that alter granulation endpoint and tablet disintegration. Substitution without re-validation is a regulatory risk because release and stability data for the finished product would no longer apply.

Injectable-Grade Release, Endotoxin, and Particulate-Matter Boundaries

Injectable processing imposes operational boundaries that oral manufacture does not. MPFF-PG-90/10-I must be stored in sealed, nitrogen-flushed packaging below 25 °C and below 60% relative humidity to prevent particle agglomeration that would increase D90 and compromise Ph. Eur. 2.9.19 particulate limits. Dispersion in sterile water for injection or 0.9% sodium chloride should be evaluated case-by-case; high ionic strength promotes flocculation of the practically insoluble flavonoid particles. Terminal autoclaving at 121 °C is not recommended because hydrolytic degradation of the flavonoid skeleton accelerates under saturated steam. Aseptic filling through a 5 µm membrane filter is used only for vehicle filtration; the API suspension is not filtered through a sterilizing-grade membrane because the particle size would be retained, reducing dose uniformity. Published pharmacokinetic data for this injectable fixed combination are limited; therefore formulation-specific sterility, endotoxin, particulate, and dissolution data should be generated before scale-up. The injectable subgrade is not intended for direct injection as bulk powder; it is an API for further sterile manufacturing.